Clinical Trial Update: An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) [Phase 4]

View source ↗

Summary

Phase 4 study comparing 20 mg esomeprazole given orally versus intravenously (15-minute infusion) and their effects on basal and pentagastrin-stimulated acid ou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Nexium (esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: GERD | Phase 4 | Status: COMPLETED